Citations

Clear

31 citation(s) found for "Thomas, Daniel".

Single-Hit TP53mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History
Shah, Syed , Abdelmajid, Maymona, Rud, Danielle, Chhetri, Rakchha , Reichard, Kaaren K. , Wiseman, Thomas, Al‐Kali, Aref , Foran, James M. , Yi, Cecilia Y. Arana , Gangat, Naseema , Patnaik, Mrinal M. , Tefferi, Ayalew , He, Rong , Hiwase, Devendra , Baranwal, Anmol , Kutyna, Monika , Hahn, Christopher N , Chen, Dong , Wiseman, Thomas, Brown, Anna , Scott, Hamish S. , Yeung, David , Ross, David M , THOMAS, DANIEL W. , Alkhateeb, Hassan B. , Yi, Cecilia Arana , Kok, Chung Hoow , Shah, Meera

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4608-4608

10.1182/blood-2023-187905 Get It

BACKGROUND: Recent World Health Organization (WHO) classifications (5 th edition), International Consensus Classification (ICC) recognized TP53-mutated ( TP53mut) myeloid neoplasms (MNs) as a distinct subcategory, acknowledging their uniformly poor outcomes. However, there are critical differences between the two guidelines in how TP53 allelic status is assigned. Both WHO-5 and ICC acknowledged the poor outcome of multi-hit TP53mut but excluded single-hit TP53mut. These changes are driven by a pivotal study demonstrating favourable outcome of single-hit TP53mut, however this study predominantly included de novo myelodysplastic syndromes (MDS) cases (Bernard et al. Nat Med 2020). In contrast, we previously reported poor outcome of TP53mut therapy-related myeloid neoplasm (t-MN) irrespective of the allelic status of TP53 (Hiwase et al Blood 2022andShah et al BCJ 2023). Finally, the ICC removed the subcategory of “therapy-related,” substituting it with diagnostic qualifiers instead. The WHO has grouped t-MN with secondary MN and renamed it as “myeloid neoplasm post cytotoxic therapy,” with the assertion that only multi-hit T P53mut MDS occurring post-cytotoxic therapy have poor outcome compared with single-hit. METHODS: We analyzed one of the largest international cohorts of TP53mut MN (n=544) with full characterization of TP53mut allele status utilizing uniform ICC criteria and similar large numbers of de novo and t-MN cases managed at Mayo Clinic Enterprise (USA) and South Australian MDS Registry, Adelaide (Australia) with clinical, integrated genomic profiling, and long-term follow-up. RESULTS: In our cohort of TP53mut MN (n=544), 475 (87.3%) MN had TP53mut variant allele frequency (VAF) of ≥10% and thus satisfied ICC criteria for TP53mut MN. Majority of TP53mut t-MN presented with MDS (bone marrow (BM) blasts 0-9%) compared de novo MN (62% vs. 48%; P=0.0012). While acute myeloid leukemia (AML) (BM blasts ≥20%) were more prevalent in TP53mutde novo MN compared to t-MN (38% vs. 24%; P= 0.001) and there was no difference in frequency of MDS/AML (BM blasts 10-19%) between the two cohorts (14% vs. 14%; P=0.8) ( Figure 1A). Majority of TP53mut were observed in the DNA-binding domain in t-MN and de novo MN (95% vs. 96.2%; P=0.48). However, mutations in Tetramer Domain were more frequent in t-MN (4.3% vs. 0.3%; P=0.002), whereas those in the TAD2 domain were more frequent in de novo TP53mut MN (2.4 vs. 0%; P =0.006). Integrating the mutation, conventional G-banding cytogenetic, copy number variation (CNV), FISH, and SNP array analysis, TP53mut MDS (BM blast 0-9%; n=260) were classified as multi-hit (n=179, 68.9%) or multi-equivalent (n=35, 13.5%) and single-hit (n=46, 17.7%) (Arber et al. Blood 2022). Striking enrichment of multi-hit/multi-hit equivalent was observed in TP53mut t-MDS compared to de novo MDS (91% vs. 72%; P<0.0001). While single-hit TP53mut were prevalent in de novo MDS compared to t-MDS (28% vs. 9%; P<0.0001). Importantly, median overall survival (OS) of single-hit was significantly longer than multi-hit de novo MDS (25.4 vs. 7.2 months; P=0.0002). In contrast to this we did not observe OS difference between single-hit and multi-hit TP53mut t-MDS (11.6 vs. 10.9 months; P =0.73) ( Figure 1B). CONCLUSION: Our study based on a large international cohort of T53mut MN provides compelling evidence that in contrast to de novo MDS, single hit TP53mut t-MDS is associated with poor outcome. Our data supports the consideration of single hit t-MDS as a multi-hit equivalent.
Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53-Mutations Using an Independent International Cohort
Shah, Syed , Ladon, Dariusz, Al‐Kali, Aref , Begna, Kebede H. , Litzow, Mark R. , Bardy, Peter, Patnaik, Mrinal M. , Foran, James M. , He, Rong , Gangat, Naseema , Yi, Cecilia Y. Arana , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Shah, Meera , Kutyna, Monika , Tran, Elizabeth Ngoc Hoa , Baranwal, Anmol , Brown, Anna , Chen, Dong , Greipp, Patricia T. , Hogan, William J. , Kumar, Sharad , Yeung, David , Scott, Hamish S. , Yi, Cecilia Arana , Alkhateeb, Hassan B. , THOMAS, DANIEL W. , Hahn, Christopher N , Orazi, Attilio , Arber, Daniel A. , Kok, Chung Hoow , Hiwase, Devendra

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 3243-3243

10.1182/blood-2023-187860 Get It

BACKGROUND: Recently proposed World Health Organization (WHO, 5 th edition) and International Consensus Classification (ICC) recognized myeloid neoplasms (MN) harboring TP53-mutated ( TP53mut) as a separate entity. However, there are critical differences between the two classifications regarding allelic-status, variance allele frequency (VAF) cut-off and blast categories, that may lead to under- or overestimation of the risk. METHODS: We analyzed MN harboring TP53mut (VAF ≥2%, n=536) managed at Mayo Clinic (USA) and South Australia Health Network (Australia). ICC (Arber et al, Blood 2022) and WHO (Bluebook, Beta v2) definitions were used to stratify MN harboring TP53mut. RESULTS: Of 536 cases, 379 (71%) had myelodysplastic syndromes (MDS) (<20% blasts) and 157 (29%) had acute myeloid leukemia (AML). Using WHO, 160 (42%) of 379 were classified as MDS-bi TP53 as they harbored 2 TP53mut (n=115; 30%) or 1 TP53mut plus confirmed loss of heterozygosity (LOH) or copy neutral LOH (cnLOH) of TP53 locus (n=45; 12%). Sixty-two (16%) TP53mut MDS with VAF >49% were classified as presumptive MDS-bi TP53. Of the 157 cases with 1 TP53mut VAF ≤49%, 17 confirmed to have an intact wild-type TP53 copy and were classified as monoallelic. While 140 (89%) cases did not have copy number variation (CNV) analysis. We next evaluated the number of TP53mut cases classified differently by WHO and ICC. As WHO does not recognize TP53mut AML as a separate entity, 157 (29%) TP53mut AML were not classifiable. 46% (174/379) of the TP53mut MDS including 48 (30%), 12 (19%) and 79 (65%) of bi TP53, presumptive bi TP53 and monoallelic TP53mut MDS according to WHO were classified differently by ICC ( Figure 1A). Discordance between the two classifications were predominantly driven by: (i) The difference in VAF cut-off. Sixty patients (11%) with TP53mut VAF <10% were excluded from the ICC classification of TP53mut MN as it mandates TP53mut VAF cut-off ≥10%. 11 (18%) and 41 (68%) of these had bi TP53, monoallelic TP53mut MDS by WHO criteria while 8 (13%) had AML. Importantly, within the VAF <10% cohort, median overall survival (OS) of 2 TP53mut or 1 TP53mut with 17p13.1 (hereafter 17p) deletion or complex karyotype (CK, n=30) was significantly poor compared to 1 TP53mut VAF <10% (11.6 vs 32.4 months; P =0.002, Figure 1B), suggesting that ICC may underestimate the poor prognosis of multi-hit or multi-hit equivalent TP53mut MN with VAF <10%. (ii) The difference in bone marrow blast cut-off. The underlying assumption by WHO is that prognosis of bi TP53mut MDS is poor irrespective of blast percentage category (0-9% vs 10-19%). In contrast, ICC considers that TP53mut MDS/AML (blasts 10-19%) is associated with poor prognosis irrespective of TP53 allelic status. Median OS of TP53mut MDS with 10-19% blasts was significantly poor compared to blast 0-9% (6.4 vs 11.6 months, P <0.0001). Second, median OS of bi TP53mut was significantly poor than monoallelic TP53mut in MDS- blast 0-9% (10.1 vs 15.9 months; P =0.0001) but not in blasts 10-19% (6.8 vs 6.2 months; P =0.19). Hence, exclusion of monoallelic TP53mut MDS with blast 10-19% as TP53mut MN from the WHO classification may underestimate the poor prognosis. (iii) The difference in the definition of biallelic and multi-hit TP53 loss. 35 cases with 1 TP53mut VAF ≤49%, had 17p deletion but did not have CNV analysis to confirm the loss of TP53 locus and could not be classified further using WHO. ICC classified 18 (50%) of these cases as multi-hit. Median OS of 1 TP53mut VAF ≤49%, and 17p deletion on karyotype was significantly poor than 1 TP53mut (VAF ≤49%without 17p deletion on karyotype (6.4 vs 14.6 months, P =0.001). (iv) The difference in the definition of multi-hit equivalent. 32% (33/104) WHO defined monoallelic cases without available CNV data, were classified as multi-hit-equivalent by ICC as they harbored CK. However, WHO does not consider CK as presumptive evidence of bi TP53. Median OS of 1 TP53mut VAF ≤49% with CK was significantly poor compared to 1 TP53mut without CK (8.2 vs 26.9 months, P =0.0008). CONCLUSION: Our study provides evidence that poor prognosis of ‘multi-hit’ TP53 with VAF <10% is underestimated by ICC. On the other hand, poor prognosis of monoallelic TP53 MDS with 10-19% blasts as well as 1 TP53mut VAF ≤49% in the presence of CK is underestimated by WHO. These data suggest that both classifications can be further refined.
TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
Sharplin, Kirsty, Chhetri, Rakchha , Ladon, Dariusz, Al‐Kali, Aref , Litzow, Mark R. , Mangaonkar, Abhishek A. , Gangat, Naseema , Patnaik, Mrinal M. , Begna, Kebede, Tefferi, Ayalew , Shah, Meera , Hahn, Christopher N , Tran, Elizabeth Ngoc Hoa , Baranwal, Anmol , Kutyna, Monika , Wang, Paul Po-Shen , Alkhateeb, Hassan B. , Ross, David M , Yeung, David , Shanmuganathan, Naranie , Hogan, William J. , Kumar, Sharad , Singhal, Deepak , Brown, Anna , Scott, Hamish S. , THOMAS, DANIEL W. , Kok, Chung Hoow , Hiwase, Devendra

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799

10.1182/blood-2022-165859 Get It

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome
Chhetri, Rakchha , Al‐Kali, Aref , Gangat, Naseema , Litzow, Mark R. , Begna, Kebede, Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Tefferi, Ayalew , Shah, Meera , Hahn, Christopher N , Tran, Elizabeth Ngoc Hoa , Singhal, Deepak , Hogan, William J. , Kutyna, Monika , Alkhateeb, Hassan B. , Baranwal, Anmol , Shanmuganathan, Naranie , Kumar, Sharad , THOMAS, DANIEL W. , Kok, Chung Hoow , Hiwase, Devendra

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6964-6965

10.1182/blood-2022-168349 Get It

Genetic Architecture of Acute Myocarditis and the Overlap With Inherited Cardiomyopathy
Lota, Amrit , Hazebroek, Mark R. , Theotokis, Pantazis , Salmi, Sara, Halliday, Brian P. , Verdonschot, Job A.J. , Meena, Devendra, Owen, Ruth , Iacob, Alma, Yazdani, Momina , Hammersley, Daniel , Jones, Richard E. , Wage, Riccardo, Buchan, Rachel , Vivian, Fredrik, Hafouda, Yakeen , Noseda, Michela , Gregson, John , Mittal, Tarun , Wong, Joyce , Robertus, Jan Lukas , Baksi, A. John , Vassiliou, Vassilios S. , Pantazis, Antonis, Barton, Paul J.R. , Pennell, Dudley J. , García‐Pavía, Pablo , Ware, James S. , Prasad, Sanjay, Lota, Amrit S , de Marvao, Antonio , Hammersley, Daniel J , Wage, Riccardo , Buchan, Rachel , Vassiliou, Vassilios , Tzoulaki, Ioanna , Barton, Paul J R , Pennell, Dudley J , Garcia-Pavia, Pablo , Cooper, Leslie T , Heymans, Stephane , Ware, James S , Theotokis, Pantazis , Wassall, Rebecca, Tayal, Upasana , Marvao, Antonio de , Cleland, John G.F. , Cook, Stuart A. , Cooper, Leslie T. , Heymans, Stéphane

Mayo Clinic

Circulation | September 26, 2022 | Volume: 146 | Issue: 15 | Pages: 1123-1134

10.1161/circulationaha.121.058457 | PMID 36154167 Get It

Background: Acute myocarditis is an inflammatory condition that may herald the onset of dilated cardiomyopathy (DCM) or arrhythmogenic cardiomyopathy (ACM). We investigated the frequency and clinical consequences of DCM and ACM genetic variants in a population-based cohort of patients with acute myocarditis. Methods: This was a population-based cohort of 336 consecutive patients with acute myocarditis enrolled in London and Maastricht. All participants underwent targeted DNA sequencing for well-characterized cardiomyopathy-associated genes with comparison to healthy controls (n=1053) sequenced on the same platform. Case ascertainment in England was assessed against national hospital admission data. The primary outcome was all-cause mortality. Results: Variants that would be considered pathogenic if found in a patient with DCM or ACM were identified in 8% of myocarditis cases compared with <1% of healthy controls ( P =0.0097). In the London cohort (n=230; median age, 33 years; 84% men), patients were representative of national myocarditis admissions (median age, 32 years; 71% men; 66% case ascertainment), and there was enrichment of rare truncating variants (tv) in ACM-associated genes (3.1% of cases versus 0.4% of controls; odds ratio, 8.2; P =0.001). This was driven predominantly by DSP -tv in patients with normal LV ejection fraction and ventricular arrhythmia. In Maastricht (n=106; median age, 54 years; 61% men), there was enrichment of rare truncating variants in DCM-associated genes, particularly TTN -tv, found in 7% (all with left ventricular ejection fraction <50%) compared with 1% in controls (odds ratio, 3.6; P =0.0116). Across both cohorts over a median of 5.0 years (interquartile range, 3.9–7.8 years), all-cause mortality was 5.4%. Two-thirds of deaths were cardiovascular, attributable to worsening heart failure (92%) or sudden cardiac death (8%). The 5-year mortality risk was 3.3% in genotype-negative patients versus 11.1% for genotype-positive patients ( P adjusted =0.08). Conclusions: We identified DCM- or ACM-associated genetic variants in 8% of patients with acute myocarditis. This was dominated by the identification of DSP -tv in those with normal left ventricular ejection fraction and TTN -tv in those with reduced left ventricular ejection fraction. Despite differences between cohorts, these variants have clinical implications for treatment, risk stratification, and family screening. Genetic counseling and testing should be considered in patients with acute myocarditis to help reassure the majority while improving the management of those with an underlying genetic variant.
Temporal lobe interictal spikes disrupt encoding and retrieval of verbal memory: A subregion analysis
Camarillo‐Rodriguez, Liliana , Leenen, Iwin , Waldman, Zachary, Serruya, Mijail D. , Wanda, Paul A., Herweg, Nora A. , Kahana, Michael J. , Orosz, Iren, Podkorytova, Irina , Jobst, Barbara C. , Sheth, Sameer A. , Weiss, Shennan A. , Sperling, Michael R. , Podkorytova, Irina , Weiss, Shennan A , Sperling, Michael R , Jobst, Barbara , Rubinstein, Daniel , Lega, Bradley Charles , Gross, Robert E. , Worrell, Gregory A. , Davis, Kathryn A.

Mayo Clinic

Epilepsia | June 16, 2022 | Volume: 63 | Issue: 9 | Pages: 2325-2337

10.1111/epi.17334 | PMID 35708911 Get It

AbstractObjectiveThe medial temporal lobe (MTL) encodes and recalls memories and can be a predominant site for interictal spikes (IS) in patients with focal epilepsy. It is unclear whether memory deficits are due to IS in the MTL producing a transient decline. Here, we investigated whether IS in the MTL subregions and lateral temporal cortex impact episodic memory encoding and recall.MethodsSeventy‐eight participants undergoing presurgical evaluation for medically refractory focal epilepsy with depth electrodes placed in the temporal lobe participated in a verbal free recall task. IS were manually annotated during the pre‐encoding, encoding, and recall epochs. We examined the effect of IS on word recall using mixed‐effects logistic regression.ResultsIS in the left hippocampus (odds ratio [OR] = .73, 95% confidence interval [CI] = .63–.84, p < .001) and left middle temporal gyrus (OR = .46, 95% CI = .27–.78, p < .05) during word encoding decreased subsequent recall performance. Within the left hippocampus, this effect was specific for area CA1 (OR = .76, 95% CI = .66–.88, p < .01) and dentate gyrus (OR = .74, 95% CI = .62–.89, p < .05). IS in other MTL subregions or inferior and superior temporal gyrus and IS occurring during the prestimulus window did not affect word encoding (p > .05). IS during retrieval in right hippocampal (OR = .22, 95% CI = .08–.63, p = .01) and parahippocampal regions (OR = .24, 95% CI = .07–.8, p < .05) reduced the probability of recalling a word.SignificanceIS in medial and lateral temporal cortex contribute to transient memory decline during verbal episodic memory.
Graph theoretical measures of fast ripples support the epileptic network hypothesis
Weiss, Shennan A. , Pastore, Tomás, Orosz, Iren, Waldman, Zachary, Fried, Itzhak , Wu, Chengyuan , Sharan, Ashwini , Engel, Jerome , Sperling, Michael R. , Staba, Richard J. , Wu, Chengyuan , Sperling, Michael R , Weiss, Shennan A , Rubinstein, Daniel , Gorniak, Richard , Slezak, Diego Fernández , Worrell, Gregory A.

Mayo Clinic

Brain Communications | April 14, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcac101 | PMID 35620169 Get It

Abstract The epileptic network hypothesis and epileptogenic zone hypothesis are two theories of ictogenesis. The network hypothesis posits that coordinated activity among interconnected nodes produces seizures. The epileptogenic zone hypothesis posits that distinct regions are necessary and sufficient for seizure generation. High-frequency oscillations, and particularly fast ripples, are thought to be biomarkers of the epileptogenic zone. We sought to test these theories by comparing high-frequency oscillation rates and networks in surgical responders and non-responders, with no appreciable change in seizure frequency or severity, within a retrospective cohort of 48 patients implanted with stereo-EEG electrodes. We recorded inter-ictal activity during non-rapid eye movement sleep and semi-automatically detected and quantified high-frequency oscillations. Each electrode contact was localized in normalized coordinates. We found that the accuracy of seizure onset zone electrode contact classification using high-frequency oscillation rates was not significantly different in surgical responders and non-responders, suggesting that in non-responders the epileptogenic zone partially encompassed the seizure onset zone(s) (P &gt; 0.05). We also found that in the responders, fast ripple on oscillations exhibited a higher spectral content in the seizure onset zone compared with the non-seizure onset zone (P &lt; 1 × 10−5). By contrast, in the non-responders, fast ripple had a lower spectral content in the seizure onset zone (P &lt; 1 × 10−5). We constructed two different networks of fast ripple with a spectral content &gt;350 Hz. The first was a rate–distance network that multiplied the Euclidian distance between fast ripple-generating contacts by the average rate of fast ripple in the two contacts. The radius of the rate–distance network, which excluded seizure onset zone nodes, discriminated non-responders, including patients not offered resection or responsive neurostimulation due to diffuse multifocal onsets, with an accuracy of 0.77 [95% confidence interval (CI) 0.56–0.98]. The second fast ripple network was constructed using the mutual information between the timing of the events to measure functional connectivity. For most non-responders, this network had a longer characteristic path length, lower mean local efficiency in the non-seizure onset zone, and a higher nodal strength among non-seizure onset zone nodes relative to seizure onset zone nodes. The graphical theoretical measures from the rate–distance and mutual information networks of 22 non- responsive neurostimulation treated patients was used to train a support vector machine, which when tested on 13 distinct patients classified non-responders with an accuracy of 0.92 (95% CI 0.75–1). These results indicate patients who do not respond to surgery or those not selected for resection or responsive neurostimulation can be explained by the epileptic network hypothesis that is a decentralized network consisting of widely distributed, hyperexcitable fast ripple-generating nodes.
Abstract 10960: Genetic Overlap of Acute Myocarditis and Inherited Cardiomyopathy
Salmi, Sara, Meena, Devendra, Iacob, Alma, Jones, Richard W. , Wage, Rick, Yazdani, Momina , Wong, Joyce , Baksi, John, Pantazis, Antonios , Prasad, Sanjay, Lota, Amrit , Hazebroek, Mark R. , Theotokis, Pantazis , Wassall, Rebecca, Halliday, Brian P. , Tayal, Upasana , Verdonschot, Job A.J. , Marvao, Antonio de , Hammersley, Daniel , Jones, Richard, Buchan, Rachel , Noseda, Michela , Mittal, Tarun , Robertus, Jan Lukas , Vassiliou, Vassilios S. , Tzoulaki, Ioanna , Cleland, John G.F. , Barton, Paul J.R. , Cook, Stuart A. , Pennell, Dudley J. , Garcia-Pavia, Pablo , Cooper, Leslie T. , Heymans, Stéphane , Ware, James S.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10960 Get It

Background: Myocarditis may predispose to dilated cardiomyopathy (DCM) and sudden cardiac death (SCD). Familial data indicate a potential genetic susceptibility shared with arrhythmogenic cardiomyopathy (ACM). We present the first large-scale genotype-phenotype study of adults with acute myocarditis. Methods: A cohort comprising 336 consecutive patients with acute myocarditis was enrolled in London and Maastricht. All participants underwent targeted DNA sequencing for well-characterised cardiomyopathy-associated genes. The burden of rare protein altering variants (PAV) in ACM genes, DCM genes, and TTN specifically, were compared with local healthy controls sequenced on the same platform (n=1053). Case ascertainment was assessed against national hospital admission data. Results: We identified rare protein-altering variants in 23% of cases compared to 16% in controls (Δ+6.8%; p=0.021), with rare truncating variants (tv) in 6% of cases compared to <1% of controls ((Δ+5%; p=0.0097). In London (n=230; median left ventricular ejection fraction (LVEF) 63%), which was representative of national myocarditis admissions, 4.8% of cases carried rare tv, particularly within ACM genes (3% cases vs 0% controls; odds ratio 8.2; p=0.001). This was predominantly driven by desmoplakin (DSP)-tv in patients with normal LVEF. In Maastricht (n=106; median LVEF 30%), rare tv in DCM genes were enriched, particularly TTN-tv found in 7% (all with LVEF<50%) compared to 1% in controls (OR 3.6; p=0.0116). During a median follow-up of 1.9 years, all-cause mortality was greatest in those with a DCM variant (18% vs 4% with no variant; OR 5.0; p=0.004). Conclusion: We identified enrichment of cardiomyopathy gene variants in acute myocarditis patients, dominated by DSP-tv in those with normal LVEF and TTN-tv in those with reduced LVEF. Incorporation of genetic testing may be beneficial to identify such high-risk individuals and guide family screening in acute myocarditis patients.